Literature DB >> 24210541

Incretin levels 1 month after laparoscopic single anastomosis gastric bypass surgery in non-morbid obese type 2 diabetes patients.

Myung Jin Kim1, Hyeong Kyu Park2, Dong Won Byun2, Kyo Il Suh2, Kyung Yul Hur3.   

Abstract

PURPOSE: Bariatric surgery is an efficient procedure for the remission of type 2 diabetes (T2DM) from morbid obesity. However, in Asian countries, the mean body mass index (BMI) of T2DM patients is about 25 kg/m(2). Various data on patients undergoing gastric bypass surgery suggest that the control of T2DM after surgery occurs rapidly. We hypothesized that even in nonobese patients with T2DM, the levels of incretin and insulin changed along with the improvement of T2DM as a consequence of the gastric bypass.
MATERIALS AND METHODS: From March to December 2011, 12 nonobese patients (mean BMI; 26.2 kg/m(2)) with poorly-controlled [mean glycated hemoglobin (HbA1C); 9.5%] diabetes underwent gastric bypass surgery. Values related to diabetes, including incretin [gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1)] levels were measured before and 1 month after surgery. All values were measured in response to a 75 g oral glucose tolerance test (OGTT).
RESULTS: On average, the BMI decreased by 2.1 ± 0.7 kg/m(2). Mean HbA1C level decreased by 1.6 ± 2%. Oral glucose-stimulated insulin levels increased and GLP-1 levels also increased significantly. Oral glucose-stimulated GIP levels decreased sharply.
CONCLUSION: Soon after gastric bypass in nonobese T2DM patients, control of T2DM is achieved. The incretin release after oral glucose is improved. This could be a consequence of changes of the enteroinsular axis, particularly in the incretins.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  gastric bypass; incretin; metabolic surgery; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2013        PMID: 24210541     DOI: 10.1016/j.asjsur.2013.09.008

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  8 in total

Review 1.  Bariatric surgery and obesity: influence on the incretins.

Authors:  B Laferrère
Journal:  Int J Obes Suppl       Date:  2016-11-16

2.  Similar Gut Hormone Secretions Two Years After One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass: a Pilot Study.

Authors:  Claire Carette; Johanne Le Beyec; David De Bandt; Claire Rives-Lange; Yvann Frigout; Damien Bergerot; Anne Blanchard; Maude Le Gall; Jean-Marc Lacorte; Jean-Marc Chevallier; Sébastien Czernichow; Tigran Poghosyan
Journal:  Obes Surg       Date:  2022-01-07       Impact factor: 4.129

3.  Mini Gastric Bypass-One Anastomosis Gastric Bypass (MGB-OAGB)-IFSO Position Statement.

Authors:  Maurizio De Luca; Tiffany Tie; Geraldine Ooi; Kelvin Higa; Jacques Himpens; Miguel-A Carbajo; Kamal Mahawar; Scott Shikora; Wendy A Brown
Journal:  Obes Surg       Date:  2018-05       Impact factor: 4.129

Review 4.  Efficacy of Laparoscopic Mini Gastric Bypass for Obesity and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Yingjun Quan; Ao Huang; Min Ye; Ming Xu; Biao Zhuang; Peng Zhang; Bo Yu; Zhijun Min
Journal:  Gastroenterol Res Pract       Date:  2015-06-17       Impact factor: 2.260

Review 5.  Metabolic Surgery in Korea: What to Consider before Surgery.

Authors:  Mi Kyung Kim; Yoonseok Heo
Journal:  Endocrinol Metab (Seoul)       Date:  2017-09

6.  Rapid changes in neuroendocrine regulation may contribute to reversal of type 2 diabetes after gastric bypass surgery.

Authors:  Petros Katsogiannos; Prasad G Kamble; Urban Wiklund; Magnus Sundbom; Daniel Espes; Ulf Hammar; F Anders Karlsson; Maria J Pereira; Jan W Eriksson
Journal:  Endocrine       Date:  2020-01-26       Impact factor: 3.633

Review 7.  Metabolic Outcomes of Surgery for Non-Obese Type 2 Diabetes.

Authors:  Kyung Yul Hur
Journal:  J Minim Invasive Surg       Date:  2020-06-15

8.  Changing Treatment Paradigm of Type 2 Diabetes.

Authors:  Kyung Yul Hur
Journal:  J Minim Invasive Surg       Date:  2020-09-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.